Venus Remedies Limited has recommended a final dividend of ₹10 per equity share, equivalent to 100% of the face value, for the financial year ended March 31, 2026. The dividend will be paid to shareholders whose names appear in the Register of Members or the list of beneficial owners provided by depositories as of the close of business hours on Friday, August 7, 2026, which has been fixed as the record date. The company stated that the dividend will be disbursed within 30 days from the date of the ensuing Annual General Meeting.

The Board of Directors has scheduled the 37th Annual General Meeting (AGM) for Thursday, August 20, 2026, at 11:30 pm IST. The meeting will be conducted via video conferencing to transact the business set forth in the notice. Members will have the opportunity to cast their votes on the resolutions through an e-voting system, with detailed procedures to be outlined in the AGM notice.

In compliance with regulatory circulars, the notice of the AGM and the Annual Report for FY 2025-26 will be sent via email to members whose email addresses are registered with the company, its Registrar and Share Transfer Agent (RTA) MUFG Intime India Private Limited, or the depositories. Physical letters containing the web-link to access these documents will be sent to members who have not registered their email addresses.

The company has advised members to validate and update their bank account details and other KYC information to ensure the direct credit of dividends. Members holding shares in physical form must submit requisite forms to the RTA, while those holding shares in dematerialized form must update their details with their respective depository participants. The company emphasized that dividends will be paid only through electronic mode upon the updation of KYC and bank account details.

Venus Remedies Limited also noted that tax will be deducted at source (TDS) on the dividend payment in accordance with the Income Tax Act, 2025. The applicable tax rate will depend on the residential status of the members and the documents submitted. A detailed note regarding the tax rates and required documentation will be included in the notes to the AGM notice.

Venus Remedies reported a consolidated net profit of ₹102.78 crore for the financial year ended March 31, 2026, marking a substantial increase from ₹45.31 crore in the prior year. Revenue from operations for the period stood at ₹769.60 crore, compared to ₹652.89 crore in FY25, while total income increased to ₹782.18 crore from ₹668.84 crore. The company's board has recommended a final dividend of ₹10 per equity share, subject to shareholder approval at the upcoming Annual General Meeting scheduled for August 20, 2026.

The standalone financial results for FY26 reflected a similar upward trajectory, with net profit reaching ₹99.31 crore, up from ₹52.55 crore in the previous year. Standalone revenue from operations grew to ₹768.73 crore from ₹644.47 crore. The statutory auditors, J.K. Jain & Associates, issued an unmodified opinion on both the standalone and consolidated financial results, confirming compliance with Indian Accounting Standards and SEBI Listing Regulations.

Annual Financial Performance

The following table outlines the consolidated financial performance for the year ended March 31, 2026, compared to the previous year:

Q4 Quarterly Performance

Venus Remedies delivered a strong quarterly performance, with consolidated net profit more than doubling to ₹47.49 crore in Q4 compared to ₹21.00 crore in the same period of the previous year. Revenue for the quarter rose to ₹259.40 crore from ₹197.66 crore year-on-year, reflecting robust top-line growth. EBITDA for the quarter expanded significantly to ₹68.37 crore from ₹35.77 crore, while EBITDA margin improved sharply to 25.86% from 18.10% in the year-ago period.

Corporate Governance and Appointments

The board approved the re-appointment of Dr. (Mrs.) Manu Chaudhary as Joint Managing Director for a period of five years effective from October 1, 2026, and Dr. (Mrs.) Savita Gupta as Non-Executive Independent Director for a second term of five years effective from December 29, 2026. Additionally, Mr. Saransh Chaudhary was appointed as an Additional Director (Whole Time Director) and Dr. Gurminder Singh Bedi as an Additional Director (Non-Executive Independent Director), both for five years starting May 26, 2026. All appointments are subject to shareholder approval.

The board also appointed M/s C. L. Bansal & Associates as Cost Auditors and M/s Mehra Goel & Co as Internal Auditors for FY 2026-27. Furthermore, the company proposed adopting new Memorandum and Articles of Association to align with the Companies Act, 2013, pending shareholder approval. The trading window for designated persons remains closed until 48 hours after the declaration of financial results.